Literature DB >> 26270441

Prognostic Value of Ki-67 Labeling Index and Postoperative Radiotherapy in WHO Grade II Meningioma.

Yunseon Choi1,2, Do Hoon Lim1, Jeong Il Yu1, Kyungil Jo3, Do-Hyun Nam3, Ho Jun Seol3, Jung-Il Lee3, Doo-Sik Kong3, Yeon-Lim Suh4, Heerim Nam5.   

Abstract

OBJECTIVE: This study was performed to determine the clinical significance of the Ki-67 labeling index (LI) for local control (LC) in patients with World Health Organization (WHO) grade II meningioma. We also tried to discern the effect of postoperative radiotherapy (PORT) on LC depending upon the Ki-67 LI value.
MATERIALS AND METHODS: The medical records and values of Ki-67 LIs were retrospectively reviewed for 50 patients who underwent surgical resection of intracranial WHO grade II meningiomas at Samsung Medical Center from May 2001 to December 2012. Forty-three patients (86%) were treated with immediate PORT. The median total radiation dose was 60 Gy (range, 54 to 60 Gy).
RESULTS: The median follow-up was 47.4 months. The mean Ki-67 LI was 13% (range, 1% to 47%). Twelve patients (24.0%) showed local failure, and 8 patients (16.0%) experienced local failure even after PORT. The mean Ki-67 LI was 15% in patients with local failure (n=12) and 12% in patients without local failure (n=38). The 3-year actuarial LC was 80.5%. The 3-year overall survival was 89.5%. Ki-67 LI>13% and PORT were significant prognostic factors for LC (P=0.015 and 0.009, respectively). In patients with Ki-67 LI>13% (n=17), PORT (n=14) improved LC (P<0.001). However, PORT (n=29) did not affect LC (P=0.412) for patients with Ki-67 LI≤13% (n=33).
CONCLUSIONS: Ki-67 LI can be a useful prognostic factor for LC in WHO grade II meningioma. In patients with Ki-67 LI>13%, PORT should be recommended to improve LC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 26270441     DOI: 10.1097/COC.0000000000000224

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Histopathological Spectrum of Meningiomas with Emphasis on Prognostic Role of Ki67 Labelling Index.

Authors:  Girish Solanke; Vidya Monappa; Ranjini Kudva
Journal:  Iran J Pathol       Date:  2020-04-21

2.  Ki67 Index Is the Most Powerful Factor for Predicting the Recurrence in Atypical Meningioma : Retrospective Analysis of 99 Patients in Two Institutes.

Authors:  Sang Hyuk Lee; Eun Hee Lee; Kyoung Su Sung; Dae Cheol Kim; Young Zoon Kim; Young Jin Song
Journal:  J Korean Neurosurg Soc       Date:  2022-04-14

3.  Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas.

Authors:  Qing Zhang; Zheng Wen; Ming Ni; Da Li; Ke Wang; Gui-Jun Jia; Zhen Wu; Li-Wei Zhang; Wang Jia; Liang Wang; Jun-Ting Zhang
Journal:  Front Oncol       Date:  2021-01-15       Impact factor: 6.244

4.  Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Authors:  Katherine Belanger; Timothy H Ung; Denise Damek; Kevin O Lillehei; D Ryan Ormond
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

Review 5.  An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas.

Authors:  Chae Jung Park; Seo Hee Choi; Jihwan Eom; Hwa Kyung Byun; Sung Soo Ahn; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee; Yae Won Park; Hong In Yoon
Journal:  Radiat Oncol       Date:  2022-08-22       Impact factor: 4.309

6.  Ki-67 labeling index as a prognostic marker in advanced stomach cancer.

Authors:  Sang Hyuk Seo; Kwang Hee Kim; Sang Hoon Oh; Yunseon Choi; Ki Jung Ahn; Ji Young Lee; Sang Min Lee; Jisun Park; Woo Gyeong Kim
Journal:  Ann Surg Treat Res       Date:  2018-12-26       Impact factor: 1.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.